76
|
Koechli OR, Perewusnyk G, Fehr MK, Droese S, Mueller H. ErbB-2 expression does not predict in vitro CMF-chemosensitivity of primary breast tumors. Anticancer Res 1999; 19:3977-83. [PMID: 10628340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
The predictive value of the oncogene product ErbB-2 for chemosensitivity of tumors is still unclear. We therefore correlated the in vitro chemosensitivity of breast cancer specimens from 125 patients with the respective expression levels of ErbB-2. Twenty-six percent of the patients were premenopausal. Chemosensitivity was tested with the adenosine triphosphate cell viability assay and ErbB-2 content was assessed in the same specimens by ELISA. With the cut-off value used 34% of the patients had tumors with positive ErbB-2 levels. The mean ErbB-2 amount of positive tumors was 388 U/mg +/- 254 and of negative tumors 65 U/mg +/- 36. The mean survival fractions (SF) in the chemosensitivity assay at 0.25 peak plasma concentration (PPC) of a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) were not significantly different for ErbB-2-positive and for ErbB-2-negative tumors (0.68 and 0.65, respectively (p = 0.6)). The median SF for positive tumors was 0.68 and for negative tumors 0.62, respectively. Similarly, at four times the PPC of CMF no significant differences in SF of ErbB-2-positive and -negative specimens were found (p = 0.8). Comparison of the median of ErbB-2-protein content of CMF-sensitive tumors with that of CMF-resistant tumors also yielded no significant difference. Taken together, no significant association between in vitro CMF-chemosensitivity and expression levels of ErbB-2 in tumors of patients with primary chemotherapy naive breast cancer could be determined.
Collapse
|
77
|
Balmelli-Gallacchi P, Schoumacher F, Liu JW, Eppenberger U, Mueller H, Picard D. A yeast-based bioassay for the determination of functional and non-functional estrogen receptors. Nucleic Acids Res 1999; 27:1875-81. [PMID: 10101196 PMCID: PMC148396 DOI: 10.1093/nar/27.8.1875] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The response to endocrine therapy of breast cancer is not entirely predictable from hormone receptor status alone since some point mutated or splicing variants of the estrogen receptor (ER) show altered biological activities. In order to characterize the activities of all forms of ER in a heterogeneous breast tumor, a functional assay in Saccharomyces cerevisiae was developed. Total RNA isolated from breast cancer cells and one breast cancer specimen was reverse transcribed and the ER cDNA was amplified by PCR. The products were then cloned into an expression vector by in vivo homologous recombination in yeast. The yeast strain carries a reporter gene ( ADE2 ) coupled to an estrogen response element. Activation of the reporter by ER yielded white colonies whereas lack of ER activity produced red colonies. This permitted the testing for functionality of individual ER molecules and subsequent analysis by rescuing of the ER expression plasmids and complete DNA sequencing. This simple visual test allows discrimination between wild-type ER, constitutively active ER and inactive ER.
Collapse
|
78
|
Crombag HS, Mueller H, Browman KE, Badiani A, Robinson TE. A comparison of two behavioral measures of psychomotor activation following intravenous amphetamine or cocaine: dose- and sensitization-dependent changes. Behav Pharmacol 1999; 10:205-13. [PMID: 10780833 DOI: 10.1097/00008877-199903000-00009] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
This paper presents data concerning the dose-effect relationships of intravenously administered amphetamine and cocaine on two widely used measures of psychomotor activation: locomotor crossover activity in neurologically intact rats, and rotational behavior in rats with a unilateral 6-hydroxydopamine lesion. There were marked differences in dose-effect relationships, both as a function of drug and of behavioral measure. Amphetamine produced a linear increase in rotational behavior over a wide range of doses (the highest effective dose was 76.8 times the lowest), but a linear increase in locomotor crossover activity over only a narrow dose range (the highest effective dose was only four times the lowest). In contrast, for cocaine, the dose-effect relationships for the two behaviors were very similar, but for both behaviors the effective dose range was quite narrow, the highest effective dose being only between two and four times the lowest. The data highlight the advantages and disadvantages of these measures as indices of the psychomotor activating effects of psychostimulant drugs.
Collapse
|
79
|
Mueller H, Butt HJ, Bamberg E. Force measurements on myelin basic protein adsorbed to mica and lipid bilayer surfaces done with the atomic force microscope. Biophys J 1999; 76:1072-9. [PMID: 9916039 PMCID: PMC1300057 DOI: 10.1016/s0006-3495(99)77272-3] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The mechanical and adhesion properties of myelin basic protein (MBP) are important for its function, namely the compaction of the myelin sheath. To get more information about these properties we used atomic force microscopy to study tip-sample interaction of mica and mixed dioleoylphosphatidylserine (DOPS) (20%)/egg phosphatidylcholine (EPC) (80%) lipid bilayer surfaces in the absence and presence of bovine MBP. On mica or DOPS/EPC bilayers a short-range repulsive force (decay length 1.0-1.3 nm) was observed during the approach. The presence of MBP always led to an attractive force between tip and sample. When retracting the tip again, force curves on mica and on lipid layers were different. While attached to the mica surface, the MBP molecules exhibited elastic stretching behavior that agreed with the worm-like chain model, yielding a persistence length of 0.5 +/- 0.25 nm and an average contour length of 53 +/- 19 nm. MBP attached to a lipid bilayer did not show elastic stretching behavior. This shows that the protein adopts a different conformation when in contact with lipids. The lipid bilayer is strongly modified by MBP attachment, indicating formation of MBP-lipid complexes and possibly disruption of the original bilayer structure.
Collapse
|
80
|
Abstract
The discovery and cloning of the cytokine tumor necrosis factor alpha (TNF) gave rise to new hopes for a significant victory in the war against cancer. Preclinical in vitro studies in cell cultures and in vivo studies in animal models demonstrated the antitumor capacities of TNF. Although clinical studies were largely made possible by the availability of recombinant TNF, phase I and II clinical trials showed very quickly that the systemic administration of TNF induced severe side effects mainly due to its pleiotropic action on immunocompetent cells. The clinical manifestations of the side effects were similar to those observed during a severe infection and inflammation. Very recently, lessons from these clinical studies yielded refined approaches whereby the toxicity of TNF is limited through local administration, a combination with other therapeutic regimens and targeted gene therapy. These new approaches are slated for larger clinical trials and in the near future might demonstrate the limited but powerful usefulness of TNF as an antineoplastic agent for different types of cancer.
Collapse
|
81
|
Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens JA, Eppenberger-Castori S. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998; 16:3129-36. [PMID: 9738585 DOI: 10.1200/jco.1998.16.9.3129] [Citation(s) in RCA: 161] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To compare the prognostic impact of tumor angiogenesis factors (vascular endothelial growth factor [VEGF], angiogenin, and basic fibroblast growth factor [bFGF]), tumor proteolysis factors (urokinase-type plasminogen activator [uPA] and plasminogen activator inhibitor-1 [PAI-1]), and conventional tumor markers (stage, grade, and steroid receptors) in early breast cancer. PATIENTS AND METHODS In the primary clinical study, tumor angiogenesis and other factors were detected in frozen biopsies from 305 primary breast tumors. VEGF expression was assessed by chemiluminescence immunosorbent assay (ICMA); angiogenin, bFGF, uPA, and PAI-1 by enzyme-linked immunosorbent assay (ELISA); and steroid receptors (estrogen receptor [ER] and progesterone receptor [PgR]) by enzyme immunoassay (EIA). In the validating clinical study, another set of 190 node-negative primary breast tumor samples were collected at a separate institution. RESULTS Univariate analysis of the primary study showed that VEGF levels were positively correlated with recurrence (P < .001). Angiogenin levels were positively correlated with disease relapse (P < .005) for the overall collective group, but not within the node-negative subset. No significant correlations were found between tumor bFGF levels and patient survival. In multivariate regression analysis, the only independent predictors of relapse-free survival (RFS) were VEGF, uPA, and lymph node status. In the validation set, the distribution of VEGF and uPA values were similar to those in the primary study; low expression of both VEGF and uPA identified patients with a < or = 20% likelihood of recurrence within 7 years. CONCLUSION Separate primary and validating clinical studies concur that tumor VEGF level is the most important prognostic parameter among several markers of tumor angiogenesis and proteolysis.
Collapse
|
82
|
Gallacchi P, Schoumacher F, Eppenberger-Castori S, Von Landenberg EM, Kueng W, Eppenberger U, Mueller H. Increased expression of estrogen-receptor exon-5-deletion variant in relapse tissues of human breast cancer. Int J Cancer 1998; 79:44-8. [PMID: 9495357 DOI: 10.1002/(sici)1097-0215(19980220)79:1<44::aid-ijc9>3.0.co;2-w] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
A substantial percentage (30-70%) of human breast carcinomas that initially respond to endocrine therapy acquire resistance during the treatment. Many patients with tumor progression despite treatment with anti-estrogen tamoxifen show continued expression of estrogen receptors (ER) and/or progesterone receptors (PgR) in the relapse tissue. This indicates that, in these tumors, mechanisms other than loss of ER expression are responsible for treatment failure. We have investigated the occurrence and frequency of the exon-5-deletion variant (d5) of ER in human breast-cancer biopsies and in normal tissues. In all normal and tumor tissues tested, both wild-type (wt) and d5 were detected, indicating that expression of the d5 variant is a naturally occurring polymorphism. However, the primary tumors of patients who relapse within 15 months (n = 13) express higher ratios of d5 than do those of patients with no relapse during the same period (p = 0.4, n = 19), though this difference is statistically not significant. A significant increase in the expression level of d5 was determined in relapse as compared with the respective primary tumor (p = 0.02). These data indicate that increased expression of the ER exon-5-deletion variant in relapse tissues might be due to clonal selection of cells resistant to anti-estrogen treatment.
Collapse
|
83
|
Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 1998; 58:622-5. [PMID: 9485011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Telomerase, a ribonucleoprotein complex, adds hexameric repeats called telomeres to the growing ends of chromosomal DNA. The enzyme telomerase activity is present in a vast majority of tumors but is repressed in most normal tissues. Recently, two groups have reported the molecular cloning of the putative catalytic subunit (hEST2/hTRT) of the telomerase gene. We investigated the expression of this gene in diverse tumor-derived cell lines and tumors as well as in various normal tissues. The expression of hEST2/hTRT was detectable in tumor-derived cell lines, primary breast tumors, pancreatic tumors, and kidney tumors. Furthermore, the expression of hEST2/hTRT was down-regulated in response to a differentiation inducer. However, several normal tissues also expressed varying levels of hEST2/hTRT. Early passage cultures of endothelial fibroblasts and some epithelial cells also expressed the telomerase gene, albeit at low levels. In contrast, the expression of TLP1/TP1, the human homologue of Tetrahymena p80 telomerase subunit, was similar in all of these samples. Our results indicate that the differences in expression of hEST2/hTRT in tumor versus normal cells are relative and are not absolute.
Collapse
|
84
|
Flury N, Eppenberger U, Mueller H. Tumor-necrosis factor-alpha modulates mitogen-activated protein kinase activity of epidermal-growth-factor-stimulated MCF-7 breast cancer cells. EUROPEAN JOURNAL OF BIOCHEMISTRY 1997; 249:421-6. [PMID: 9370349 DOI: 10.1111/j.1432-1033.1997.00421.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Tumor-necrosis factor(TNF)-alpha inhibited in a dose-dependent fashion the proliferation of epidermal-growth-factor(EGF)-stimulated MCF-7 breast cancer cells with an IC50 of 0.25 nM. A comparable TNF-alpha-mediated inhibition of p42/44 mitogen-activated protein (MAP) kinase activity was observed in 10 nM EGF-stimulated cells. The MAP kinase activity dropped 50% within 3 min of TNF-alpha (1 nM) addition to EGF-stimulated MCF-7 cells. EGF and TNF-alpha, when added independently, led to a transient stimulation of MAP kinase activity with maximal activations within 6-8 min and 1-2 min, respectively. These observations suggest that MAP kinase activity in EGF-stimulated MCF-7 cells is modulated by the growth-inhibitory receptor pathways of TNF-alpha. Phosphorylation measurements on western blots determined the involvement of several individual MAP kinases, namely p42/44 MAP kinases, p38 MAP kinase and c-Jun N2-terminal kinase 1 (JNK1), in EGF and TNF-alpha-induced signalling. Phosphorylation of p42 and p38 MAP kinases only was observed after treatment with either TNF-alpha or EGF. A combination of both ligands inhibited p42 and p38 MAP kinase phosphorylation in MCF-7 cells. In contrast, no JNK1 phosphorylation was detected in these cells. Simultaneous addition of okadaic acid, a potent inhibitor of phosphatases 1 and 2A, blocked the decay of EGF-stimulated MAP kinase activity over 40 min. TNF-alpha added to EGF-stimulated and okadaic-acid-treated cells increased the MAP kinase activity twofold within 1 min. Similarly, okadaic acid treatment partly reverted the TNF-alpha-inhibited growth of MCF-7 cells. These experiments suggest that phosphatases are involved in the rapid shut-down by TNF-alpha of p42 MAP kinase activity.
Collapse
|
85
|
Mueller H, Liu R, David F, Eppenberger U. Selective modulation of protein kinase A and protein kinase C activities in epidermal growth factor (EGF)-stimulated MCF-7 breast cancer cells. Biol Chem 1997; 378:1023-9. [PMID: 9348112 DOI: 10.1515/bchm.1997.378.9.1023] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
In human MCF-7 breast cancer cells, both protein kinase A (PKA) and different members of the protein kinase C (PKC) family are stimulated upon binding of epidermal growth factor (EGF) to cell surface receptors. Selective stimulation of calcium-dependent PKCs with 10(-6) to 10(-9) M Thymeleatoxin significantly increased the proliferation rate of MCF-7 cells over 5 days in culture. This stimulation was blocked by the PKC antagonist Chelerythrine. In contrast, selective activation of PKA by addition of 1 mM dibutyryl cyclic AMP (dBcAMP) did not affect the proliferation rate of MCF-7 cells. Similarly, activation of the adenylate cyclase by 1 microM Forskolin and inhibition of PKA by the cyclic AMP analogue Rp-cAMPS did not modulate the proliferation rate of these cells. Activation of PKC stimulated the expression of the immediate early gene c-fos but c-myc expression was not significantly enhanced. On the other hand, PKA activation increased both c-myc and c-fos expression in MCF-7 cells. These results suggest that PKA activation and c-myc expression are not obligatory for proliferation of MCF-7 cells.
Collapse
|
86
|
Sloan MA, Price TR, Terrin ML, Forman S, Gore JM, Chaitman BR, Hodges M, Mueller H, Rogers WJ, Knatterud GL, Braunwald E. Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II pilot and randomized clinical trial combined experience. Stroke 1997; 28:1107-14. [PMID: 9183334 DOI: 10.1161/01.str.28.6.1107] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND AND PURPOSE Ischemic cerebral infarction (CI) is a serious complication of acute myocardial infarction (MI). Little information exists on CI after thrombolytic therapy for MI. METHODS Of 3924 MI patients treated with recombinant tissue plasminogen activator (rt-PA) and heparin, 29 (0.7%) developed CI after treatment. All CI patients had detailed neurological evaluations, and 27 (93%) had CT scans centrally reviewed. RESULTS Age range was 40 to 74 years (mean, 60 years); 25 patients (86%) were men, and 22 (76%) were white. The electrocardiographic location of MI was anterior in 22 (76%) and nonanterior in 7 (24%). Five CIs occurred within 6 hours, 4 between 6 to 24 hours, 8 during the remainder of the first week, 10 during the second week, and 2 others distributed over the 4 weeks after study entry. Six of 29 CIs did not involve the cerebral cortex; 9 patients (31%) had multiple CIs. Of 28 CIs thought to be embolic in origin, 17 showed strong evidence for at least one cardiac abnormality (mural clot, wall-motion abnormality, aneurysm, or atrial fibrillation) known to be associated more specifically with embolism than MI. Eight of 27 CIs (30%) with CT scans had hemorrhagic transformation of varying degrees; 5 were symptomatic. CONCLUSIONS The time of occurrence and sites of CI after rt-PA and heparin therapy for acute MI are similar to those reported during the prethrombolytic era.
Collapse
|
87
|
Zhang Y, Landas K, Mueller H, Angulo JA. Progressive augmentation of striatal and accumbal preprotachykinin mRNA levels by chronic treatment with methamphetamine and effect of concurrent administration of the N-methyl-D-aspartate receptor antagonist MK-801. Neuropharmacology 1997; 36:325-34. [PMID: 9175611 DOI: 10.1016/s0028-3908(97)00005-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We have assessed the time course of repeated administration of methamphetamine (METH; 4 mg/kg) and withdrawal on the levels of preprotachykinin (PPT) and preproenkephalin (PPE) mRNA abundance in the caudate-putamen (CPu) and nucleus accumbens (NAc) of the rat brain by in situ hybridization histochemistry. Neostriatal PPT mRNA levels rose gradually between days 1 and 6 of treatment, with the greatest elevation observed at day 6. After 6 days of daily injections twice per day, PPT mRNA increases in dorsomedial (172%) and ventromedial (196%) aspects of the CPu were significantly higher than in dorsolateral (147%) and ventrolateral (135%) subdivisions. Similarly, PPT mRNA levels were increased in the anterior CPu (163%) and NAc (121%). Concurrent administration of METH and the NMDA receptor antagonist MK-801 attenuated METH-induced increases of PPT mRNA in all aspects of the CPu at day 6 of treatment and completely prevented the increase in the NAc. Moreover, animals treated with METH for 6 days and then withdrawn for 15 days displayed PPT mRNA levels in striatum and accumbens that were statistically indistinguishable from those of controls. Adjacent sections from the same brains were used to assess PPE mRNA levels. PPE mRNA levels were transiently elevated in dorsal and ventral aspects of the CPu at day 1 and decayed to control levels at days 3 and 6. The results demonstrate that progressive treatment with methamphetamine causes stepwise elevation of preprotachykinin mRNA levels in the neostriatum. Moreover, the increase of neuropeptide mRNA shows selectivity, since PPE mRNA levels did not display progressive accumulation of message. The effects of progressive METH treatment on neostriatal PPT mRNA expression decay when the drug is withdrawn, suggesting that this neuropeptidergic system may not represent a neuroadaptation sustaining enduring sensitization to amphetamines, but may play a role in the progressive augmentation of locomotor activity elicited by this class of drug.
Collapse
|
88
|
Spuergin P, Walter M, Schiltz E, Deichmann K, Forster J, Mueller H. Allergenicity of alpha-caseins from cow, sheep, and goat. Allergy 1997; 52:293-8. [PMID: 9140519 DOI: 10.1111/j.1398-9995.1997.tb00993.x] [Citation(s) in RCA: 74] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The allergic potential of alpha-caseins from bovine, ovine, and goat's milk sharing more than 85% identical amino acids was compared. Caseins were purified by anion-exchange chromatography and used for a specific IgE and IgG ELISA with diluted human sera. Sera were from 17 children with immediate-type allergy to cow's milk, from 59 children with atopy but without food allergy, and from 27 healthy children without atopy disease. The sera of cow's milk-allergic children showed a significantly higher IgE and IgG binding to alpha-caseins from all three species than the sera of the other groups. All groups showed an increased antibody binding to bovine alpha-casein compared to the sheep and goat proteins, but the differences were significant only in the groups of atopic children and of healthy controls. Furthermore, inhibition of the IgE binding to bovine alpha-casein with alpha-casein from cow, goat, and sheep revealed that the alpha-casein from these species are highly cross-reactive; on the basis of the small differences in their primary structure. In conclusion, the milk of goat and sheep harbor an allergic potential and is not suitable for the nutrition of milk-allergic patients.
Collapse
|
89
|
Mueller H, Flury N, Liu R, Scheidegger S, Eppenberger U. Tumour necrosis factor and interferon are selectively cytostatic in vitro for hormone-dependent and hormone-independent human breast cancer cells. Eur J Cancer 1996; 32A:2312-8. [PMID: 9038615 DOI: 10.1016/s0959-8049(96)00273-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Since experimental studies have shown that tumour necrosis factor-alpha (TNF-alpha) has potent anti-tumour activity that can be potentiated with cytokines, we tested the efficacy of TNF-alpha with interferon-gamma (IFN-gamma) on different human breast cancer cell lines, particularly comparing hormone-dependent and -independent phenotypes. TNF-alpha inhibited the growth of hormone-dependent human MCF-7, ZR-75-1 and T47-D breast cancer cells with a half maximal concentration of 0.25 nM. In contrast, the growth of hormone-independent cells MDA-MB-231 and HS578T was not affected by TNF-alpha alone, but a synergistic inhibition was observed when using IFN-gamma and TNF-alpha together. The mRNA for the proto-oncogene C-MYC, as an intracellular indicator of cell activation, was significantly increased in MCF-7 cells in the presence of TNF-alpha. In MDA-MB-231 cells this mRNA was increased only in the presence of both TNF-alpha and IFN-gamma, without a change in the number of surface TNF receptors. These findings indicate that TNF-alpha treatment in combination with IFN-gamma may provide a successful approach to overcome the cellular heterogeneity of advanced breast tumours.
Collapse
|
90
|
Seipp S, Wahl R, Mueller H, Stremmel W, Theilmann L, Goeser T. Sequence analysis of hepatitis GB virus C (GBV-C) isolates from 14 patients. Virus Res 1996; 46:81-8. [PMID: 9029780 DOI: 10.1016/s0168-1702(96)01377-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
In 1995, a new human hepatitis virus belonging to the family Flaviviridae was described and designated hepatitis GBV-C. To investigate variations within the genome of GBV-C and to study the relationship of GBV-C to GBV-A/B or hepatitis C virus (HCV), we established a detection system using reverse transcriptase polymerase chain reaction (RT-PCR) of the putative helicase region (NS3). So far, isolates derived from 14 different GBV-C-positive sera were analyzed (GBV-C/S3-36), showing 80.1-89.4% (mean: 85%) identical nucleotides. The deduced amino acid sequences revealed 97.3% homology. Nucleotide sequences of GBV-C/S3-36 revealed about 60% identity to GBV-A as well as to HCV, but only 56% identity to GBV-B. Amino acid sequences revealed 73.4 and 68.6% similarity to GBV-A and GBV-B, respectively, but a slightly higher percentage of 78.5% to HCV sequences. Thus, according to the putative GBV-C helicase sequence, a subtyping of GBV-C into different genotypes may be necessary.
Collapse
|
91
|
Mueller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 1996; 16:3845-8. [PMID: 9042268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Mutational loss of p53 tumor suppressor functions has been observed in a wide range of neoplasms and was associated with either enhanced or decreased chemosensitivity of affected tumors. The dual role of wild-type p53 as a DNA repair initiator and a trigger for apoptosis raises the possibility that appropriately designed chemotherapy could be selectively applied against p53-defective tumor cells. The cytotoxic effects of DNA-crosslinking chemotherapeutica such as cisplatin could be enhanced by mutated p53 which is no longer able to repair drug-induced DNA damage. In contrast, DNA synthesis blockers such as fluorouracil can induce apoptosis through p53-dependent mechanisms. Thus, loss of p53 functions results in decreased sensitivity to this type of drugs. Clinical studies will reveal the role of abberant p53 in the efficacy of chemotherapy for individual patients.
Collapse
|
92
|
Steingart RM, Forman S, Coglianese M, Bittner V, Mueller H, Frishman W, Handberg E, Gambino A, Knatterud G, Conti CR. Factors limiting the enrollment of women in a randomized coronary artery disease trial. The Asymptomatic Cardiac Ischemia Pilot Study (ACIP) Investigators. Clin Cardiol 1996; 19:614-8. [PMID: 8864334 DOI: 10.1002/clc.4960190807] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND AND HYPOTHESIS Although it is recognized that women have been underrepresented in clinical trials of cardiovascular disease, the reasons for their limited enrollment have not been elucidated. METHODS A prospective tracking system was established in the Asymptomatic Cardiac Ischemia Pilot study (ACIP) to monitor recruitment and identify protocol issues that interfered with the recruitment of women. Patients with stress test evidence for ischemia during the course of routine clinical care were screened for asymptomatic ischemia with an ambulatory electrocardiogram (ECG). RESULTS Those with at least one episode of asymptomatic ischemia and angiographic evidence of coronary artery disease suited for revascularization could be randomized. Women comprised only 17% of the 1,820 patients screened for asymptomatic ischemia, and only 14% of the 558 patients randomized. The limited number of women screened for ischemia was largely due to the limited number of women (25% of all patients) found to have test evidence for ischemia or coronary artery disease suited for revascularization during the course of routine clinical care. Once patients were identified as having ischemia on stress test and ambulatory ECG, the major difference in eligibility was the difference in disqualifying angiograms, occurring 21/2 times as frequently in women as in men (p < 0.001). CONCLUSION The percentage of women recruited was lower than the prevalence of ischemic heart disease in the general population because at participating centers (1) women were found to have ischemia less often than men during the course of routine clinical care, and (2) screening tests for ischemia were less predictive of protocol-defined coronary disease in women than in men.
Collapse
|
93
|
Adam W, Adye T, Agasi E, Ajinenko I, Aleksan R, Alekseev GD, Alemany R, Allport PP, Almehed S, Amaldi U, Amato S, Andreazza A, Andrieux ML, Antilogus P, Apel WD, Arnoud Y, Åsman B, Augustin JE, Augustinus A, Baillon P, Bambade P, Barao F, Barate R, Barbi M, Bardin DY, Baroncelli A, Barring O, Barrio JA, Bartl W, Bates MJ, Battaglia M, Baubillier M, Baudot J, Becks KH, Begalli M, Beilliere P, Belokopytov Y, Benvenuti AC, Berggren M, Bertini D, Bertrand D, Bianchi F, Bigi M, Bilenky MS, Billoir P, Bloch D, Blume M, Bolognese T, Bonesini M, Bonivento W, Booth PSL, Borisov G, Bosio C, Botner O, Boudinov E, Bouquet B, Bourdarios C, Bowcock TJV, Bozzo M, Branchini P, Brand KD, Brenke T, Brenner RA, Bricman C, Brown RCA, Bruckman P, Brunet JM, Bugge L, Buran T, Burgsmueller T, Buschmann P, Buys A, Cabrera S, Caccia M, Calvi M, Camacho Rozas AJ, Camporesi T, Canale V, Canepa M, Cankocak K, Cao F, Carena F, Carroll L, Caso C, Castillo Gimenez MV, Cattai A, Cavallo FR, Chabaud V, Charpentier P, Chaussard L, Chauveau J, Checchia P, Chelkov GA, Chen M, Chierici R, Chliapnikov P, Chochula P, Chorowicz V, Chudoba J, Cindro V, Collins P, Contreras JL, Contri R, Cortina E, Cosme G, Cossutti F, Crawley HB, Crennell D, Crosetti G, Maestro J, Czellar S, Dahl-Jensen E, Dahm J, Dalmagne B, Dam M, Damgaard G, Dauncey PD, Davenport M, Silva W, Defoix C, Deghorain A, Ricca G, Delpierre P, Demaria N, Angelis A, Boer W, Brabandere S, Clercq C, Vaissiere C, Lotto B, Min A, Paula L, Saint-Jean C, Dijkstra H, Ciaccio L, Djama F, Dolbeau J, Donszelmann M, Doroba K, Dracos M, Drees J, Drees KA, Dris M, Durand JD, Edsall D, Ehret R, Eigen G, Ekelof T, Ekspong G, Elsing M, Engel JP, Erzen B, Santo M, Falk E, Fassouliotis D, Feindt M, Fenyuk A, Ferrer A, Fichet S, Filippas TA, Firestone A, Fischer PA, Foeth H, Fokitis E, Fontanelli F, Formenti F, Franek B, Frenkiel P, Fries DC, Frodesen AG, Fruhwirth R, Fulda-Quenzer F, Fuster J, Galloni A, Gamba D, Gandelman M, Garcia C, Garcia J, Gaspar C, Gasparini U, Gavillet P, Gazis EN, Gele D, Gerber JP, Gibbs M, Gokieli R, Golob B, Gopal G, Gorn L, Gorski M, Gouz Y, Gracco V, Graziani E, Grosdidier G, Grzelak K, Gumenyuk S, Gunnarsson P, Gunther M, Guy J, Hahn F, Hahn S, Hajduk Z, Hallgren A, Hamacher K, Hao W, Harris FJ, Hedberg V, Henriques R, Hernandez JJ, Herquet P, Herr H, Hessing TL, Higon E, Hilke HJ, Hill TS, Holmgren SO, Holt PJ, Holthuizen D, Hoorelbeke S, Houlden M, Hrubec J, Huet K, Hultqvist K, Jackson JN, Jacobsson R, Jalocha P, Janik R, Jarlskog C, Jarlskog G, Jarry P, Jean-Marie B, Johansson EK, Jonsson L, Jonsson P, Joram C, Juillot P, Kaiser M, Kapusta F, Karafasoulis K, Karlsson M, Karvelas E, Katsanevas S, Katsoufis EC, Keranen R, Khokhlov Y, Khomenko BA, Khovanski NN, King B, Kjaer NJ, Klein H, Klovning A, Kluit P, Koene B, Kokkinias P, Koratzinos M, Korcyl K, Kourkoumelis C, Kouznetsov O, Kramer PH, Krammer M, Kreuter C, Kronkvist I, Krumstein Z, Krupinski W, Kubinec P, Kucewicz W, Kurvinen K, Lacasta C, Laktineh I, Lamblot S, Lamsa JW, Lanceri L, Lane DW, Langefeld P, Last I, Laugier JP, Lauhakangas R, Leder G, Ledroit F, Lefebure V, Legan CK, Leitner R, Lemoigne Y, Lemonne J, Lenzen G, Lepeltier V, Lesiak T, Libby J, Liko D, Lindner R, Lipniacka A, Lippi I, Loerstad B, Loken JG, Lopez JM, Loukas D, Lutz P, Lyons L, MacNaughton J, Maehlum G, Maio A, Malychev V, Marco J, Marco R, Marechal B, Margoni M, Marin JC, Mariotti C, Markou A, Maron T, Martinez-Rivero C, Martinez-Vidal F, Marti i Garcia S, Masik J, Matorras F, Matteuzzi C, Matthiae G, Mazzucato M, Cubbin MM, Kay RM, Nulty RM, Medbo J, Merk M, Meroni C, Meyer S, Meyer WT, Miagkov A, Michelotto M, Migliore E, Mirabito L, Mitaroff WA, Mjoernmark U, Moa T, Moeller R, Moenig K, Monge MR, Morettini P, Mueller H, Mundim LM, Murray WJ, Muryn B, Myatt G, Naraghi F, Navarria FL, Navas S, Nawrocki K, Negri P, Neumann W, Neumeister N, Nicolaidou R, Nielsen BS, Nieuwenhuizen M, Nikolaenko V, Niss P, Nomerotski A, Normand A, Novak M, Oberschulte-Beckmann W, Obraztsov V, Olshevski AG, Onofre A, Orava R, Osterberg K, Ouraou A, Paganini P, Paganoni M, Pages P, Palka H, Papadopoulou TD, Papageorgiou K, Pape L, Parkes C, Parodi F, Passeri A, Pegoraro M, Peralta L, Pernegger H, Pernicka M, Perrotta A, Petridou C, Petrolini A, Petrovyck M, Phillips HT, Piana G, Pierre F, Pimenta M, Pindo M, Plaszczynski S, Podobrin O, Pol ME, Polok G, Poropat P, Pozdniakov V, Prest M, Privitera P, Pukhaeva N, Pullia A, Radojicic D, Ragazzi S, Rahmani H, Rames J, Ratoff PN, Read AL, Reale M, Rebecchi P, Redaelli NG, Regler M, Reid D, Renton PB, Resvanis LK, Richard F, Richardson J, Ridky J, Rinaudo G, Ripp I, Romero A, Roncagliolo I, Ronchese P, Roos L, Rosenberg EI, Rosso E, Roudeau P, Rovelli T, Ruckstuhl W, Ruhlmann-Kleider V, Ruiz A, Rybicki K, Saarikko H, Sacquin Y, Sadovsky A, Sahr O, Sajot G, Salt J, Sanchez J, Sannino M, Schimmelpfennig M, Schneider H, Schwickerath U, Schyns MAE, Sciolla G, Scuri F, Seager P, Sedykh Y, Segar AM, Seitz A, Sekulin R, Shellard RC, Siccama I, Siegrist P, Simonetti S, Simonetto F, Sisakian AN, Sitar B, Skaali TB, Smadja G, Smirnov N, Smirnova O, Smith GR, Sokolov A, Solovianov O, Sosnowski R, Souza-Santos D, Spassov T, Spiriti E, Sponholz P, Squarcia S, Stanescu C, Stapnes S, Stavitski I, Stevenson K, Stichelbaut F, Stocchi A, Strauss J, Strub R, Stugu B, Szczekowski M, Szeptycka M, Tabarelli T, Tavernet JP, Tchikilev O, Thomas J, Tilquin A, Timmermans J, Tkatchev LG, Todorov T, Todorova S, Toet DZ, Tomaradze A, Tome B, Tonazzo A, Tortora L, Transtromer G, Treille D, Trischuk W, Tristram G, Trombini A, Troncon C, Tsirou A, Turluer ML, Tyapkin IA, Tyndel M, Tzamarias S, Ueberschaer B, Ullaland O, Uvarov V, Valenti G, Vallazza E, Velde CV, Apeldoorn GW, Dam P, Doninck WK, Eldik J, Vassilopoulos N, Vegni G, Ventura L, Venus W, Verbeure F, Verlato M, Vertogradov LS, Vilanova D, Vincent P, Vitale L, Vlasov E, Vodopyanov AS, Vrba V, Wahlen H, Walck C, Waldner F, Weierstall M, Weilhammer P, Weiser C, Wetherell AM, Wicke D, Wickens JH, Wielers M, Wilkinson GR, Williams WSC, Winter M, Witek M, Woschnagg K, Yip K, Yushchenko O, Zach F, Zaitsev A, Zalewska A, Zalewski P, Zavrtanik D, Zevgolatakos E, Zimin NI, Zito M, Zontar D, Zucchelli GC, Zumerle G. Study of rareb decays with the DELPHI detector at LEP. ACTA ACUST UNITED AC 1996. [DOI: 10.1007/s002880050238] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
94
|
Spuergin P, Mueller H, Walter M, Schiltz E, Forster J. Allergenic epitopes of bovine ?S1-casein recognized by human IgE and IgG. Allergy 1996. [DOI: 10.1111/j.1398-9995.1996.tb00090.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
95
|
Spuergin P, Mueller H, Walter M, Schiltz E, Forster J. Allergenic epitopes of bovine alpha S1-casein recognized by human IgE and IgG. Allergy 1996; 51:306-12. [PMID: 8836334 DOI: 10.1111/j.1398-9995.1996.tb04614.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
B-cell epitopes of bovine alpha S1-casein, one of the major allergens of cow's milk, were identified by a screening method based on synthetic peptides. According to the known amino acid sequence of alpha S1-casein, a set of 188 overlapping sequential decapeptides shifted by one amino acid was manually synthesized on polyethylene pins by the 9-fluorenyl-methoxycarbonyl (Fmoc) method. Peptides were screened by an enzyme-linked immunosorbent assay (ELISA) specific for human IgE and IgG. Bound antibodies were detected by successive incubation with up to three polyclonal antibodies, the last one conjugated to horseradish peroxidase. Tested sera were from 15 patients with acute clinical reactions to cow's milk and IgE-specific reactions to bovine alpha-casein in the ELISA and immunoblot. Sera from 10 healthy subjects without remarkable reactions to cow's milk proteins were used as controls. All sera from allergic subjects showed reactions with three regions of alpha S1-casein, corresponding to amino acids 19-30, 93-98, and 141-150. Furthermore, individual sera showed reactions with other parts of the protein. No essential differences in the epitope specificity of IgE and IgG were found. Inhibition of IgE binding to alpha S1-casein with soluble synthetic peptides confirmed the results and revealed peptide CN-2 as the most inhibiting one.
Collapse
|
96
|
Garvin AM, Mueller H, Eppenberger-Castori S, Eppenberger UR, Scott RJ. Informed consent and BRCA1 mutation detection in archived breast tumor specimens. Lancet 1996; 347:1189. [PMID: 8609789 DOI: 10.1016/s0140-6736(96)90647-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
97
|
Abreu P, Adam W, Adye T, Agasi E, Ajinenko I, Aleksan R, Alekseev GD, Alemany R, Allport PP, Almehed S, Amaldi U, Amato S, Andreazza A, Andrieux ML, Antilogus P, Apel WD, Arnoud Y, Åsman B, Augustin JE, Augustinus A, Baillon P, Bambade P, Barao F, Barate R, Barbi M, Barbiellini G, Bardin DY, Baroncelli A, Barring O, Barrio JA, Bartl W, Bates MJ, Battaglia M, Baubillier M, Baudot J, Becks KH, Begalli M, Beilliere P, Belokopytov Y, Benvenuti AC, Berggren M, Bertrand D, Bianchi F, Bigi M, Bilenky MS, Billoir P, Bloch D, Blume M, Blyth S, Bolognese T, Bonesini M, Bonivento W, Booth PSL, Borisov G, Bosio C, Bosworth S, Botner O, Boudinov E, Bouquet B, Bourdarios C, Bowcock TJV, Bozzo M, Branchini P, Brand KD, Brenke T, Brenner RA, Bricman C, Brillault L, Brown RCA, Bruckman P, Brunet JM, Bugge L, Buran T, Burgsmueller T, Buschmann P, Buys A, Cabrera S, Caccia M, Calvi M, Camacho Rozas AJ, Camporesi T, Canale V, Canepa M, Cankocak K, Cao F, Carena F, Carroll L, Caso C, Castillo Gimenez MV, Cattai A, Cavallo FR, Cerrito L, Chabaud V, Chapkin M, Charpentier P, Chaussard L, Chauveau J, Checchia P, Chelkov GA, Chen M, Chierici R, Chliapnikov P, Chochula P, Chorowicz V, Chudova J, Cindro V, Collins P, Contreras JL, Contri R, Cortina E, Cosme G, Cossutti F, Crawley HB, Crennell D, Cresetti G, Maestro JC, Czellar S, Dahl-Jensen E, Dahm J, Dalmagne B, Dam M, Damgaard G, Dauncey PD, Davenport M, Silva W, Defoix C, Deghorain A, Ricca G, Delpierre P, Demaria N, Angelis A, Boer W, Brabandere S, Clercq C, Vaissiere C, Lotto B, Min A, Paula L, Saint-Jean C, Dijkstra H, Ciaccio L, Djama F, Dolbeau J, Donszelmann M, Doroba K, Dracos M, Drees J, Drees KA, Dris M, Edsall D, Ehret R, Eigen G, Ekelof T, Ekspong G, Elsing M, Engel JP, Ershaidat N, Erzen B, Santo ME, Falk E, Fassouliotis D, Feindt M, Fenyuk A, Ferrer A, Filippas TA, Firestone A, Fischer PA, Foeth H, Fokitis E, Fontanelli F, Formenti F, Franek B, Frenkiel P, Fries DC, Frodesen AG, Fruhwirth R, Fulda-Quenzer F, Fuster J, Galloni A, Gamba D, Gandelman M, Garcia C, Garcia J, Gaspar C, Gasparini U, Gavillet P, Gazis EN, Gele D, Gerber JP, Gibbs M, Gokieli R, Golob B, Gopal G, Gorn L, Gorski M, Gouz Y, Gracco V, Graziani E, Grosdidier G, Grzelak K, Gumenyuk S, Gunnarsson P, Gunther M, Guy J, Hahn F, Hahn S, Hajduk Z, Hallgren A, Hamacher K, Hao W, Harris FJ, Hedberg V, Henriques R, Hernandez JJ, Herquet P, Herr H, Hessing TL, Higon E, Hilke HJ, Hill TS, Holmgren SO, Holt PJ, Holthuizen D, Hoorelbeke S, Houlden M, Huet K, Hultqvist K, Jackson JN, Jacobsson R, Jalocha P, Janik R, Jarlskog C, Jarlskog G, Jarry P, Jean-Marie B, Johansson EK, Jonsson L, Jonsson P, Joram C, Juillot P, Kaiser M, Kapusta F, Karafasoulis K, Karlsson M, Karvelas E, Katsanevas S, Katsoufis EC, Keranen R, Khomenko BA, Khovanski NN, King B, Kjaer NJ, Klein H, Klovning A, Kluit P, Koene B, Kokkinias P, Koratzinos M, Korcyl K, Kostioukhine V, Kourkoumelis C, Kouznetsov O, Kramer PH, Krammer M, Kreuter C, Kronkvist I, Krumstein Z, Krupinski W, Kubinec P, Kucewicz W, Kurvinen K, Lacasta C, Laktineh I, Lamblot S, Lamsa JW, Lanceri L, Lane DW, Langefeld P, Lapin V, Last I, Laugier JP, Lauhakangas R, Leder G, Ledroit F, Lefebure V, Legan CK, Leitner R, Lemoigne Y, Lemonne J, Lenzen G, Lepeltier V, Lesiak T, Liko D, Lindner R, Lipniacka A, Lippi I, Loerstad B, Loken JG, Lopez JM, Loukas D, Lutz P, Lyons L, MacNaughton J, Maehlum G, Maio A, Malychev V, Mandl F, Marco J, Marco R, Marechal B, Margoni M, Marin JC, Mariotti C, Markou A, Maron T, Martinez-Rivero C, Martinez-Vidal F, Marti i Garcia S, Masik J, Matorras F, Matteuzzi C, Matthiae G, Mazzucato M, Mc Cubbin M, Mc Kay R, Mc Nulty R, Medbo J, Merk M, Meroni C, Meyer S, Meyer WT, Michelotto M, Migliore E, Mirabito L, Mitaroff WA, Mjoernmark U, Moa T, Moeller R, Moenig K, Monge MR, Morettini P, Mueller H, Mundim LM, Murray WJ, Muryn B, Myatt G, Naraghi F, Navarria FL, Navas S, Nawrocki K, Negri P, Neumann W, Neumeister N, Nicolaidou R, Nielsen BS, Nieuwenhuizen M, Nikolaenko V, Niss P, Nomerotski A, Normand A, Novak M, Oberschulte-Beckmann W, Obraztsov V, Olshevski AG, Onofre A, Orava R, Ostankov A, Osterberg K, Ouraou A, Paganini P, Paganoni M, Pages P, Palka H, Papadopoulou TD, Papageorgiou K, Pape L, Parkes C, Parodi F, Passeri A, Pegoraro M, Pernegger H, Pernicka M, Perrotta A, Petridou C, Petrolini A, Petrovyck M, Phillips HT, Piana G, Pierre F, Pimenta M, Pindo M, Plaszczynski S, Podobrin O, Pol ME, Polok G, Poropat P, Pozdniakov V, Prest M, Privitera P, Pukhaeva N, Pullia A, Radojicic D, Ragazzi S, Rahmani H, Ratoff PN, Read AL, Reale M, Rebecchi P, Redaelli NG, Regler M, Reid D, Renton PB, Resvanis LK, Richard F, Richardson J, Ridky J, Rinaudo G, Ripp I, Romero A, Roncagliolo I, Ronchese P, Roos L, Rosenberg EI, Rosso E, Roudeau P, Rovelli T, Ruckstuhl W, Ruhlmann-Kleider V, Ruiz A, Rybicki K, Saarikko H, Sacquin Y, Sadovsky A, Sajot G, Salt J, Sanchez J, Sannino M, Schimmelpfennig M, Schneider H, Schwickerath U, Schyns MAE, Sciolla G, Scuri F, Seager P, Sedykh Y, Segar AM, Seitz A, Sekulin R, Shellard RC, Siccama I, Siegrist P, Simonetti S, Simonetto F, Sisakian AN, Sitar B, Skaali TB, Smadja G, Smirnov N, Smirnova O, Smith GR, Sosnowski R, Souza-Santos D, Spassov T, Spiriti E, Sponholz P, Squarcia S, Stanescu C, Stapnes S, Stavitski I, Stichelbaut F, Stocchi A, Strauss J, Strub R, Stugu B, Szczekowski M, Szeptycka M, Tabarelli T, Tavernet JP, Tchikilev O, Tilquin A, Timmermans J, Tkatchev LG, Todorov T, Todorova S, Toet DZ, Tomaradze A, Tome B, Tonazzo A, Tortora L, Transtromer G, Treille D, Trischuk W, Tristram G, Trombini A, Troncon C, Tsirou A, Turluer ML, Tyapkin IA, Tyndel M, Tzamarias S, Ueberschaer B, Ullaland O, Uvarov V, Valenti G, Vallazza E, Velde C, Apeldoorn GW, Dam P, Doninck WK, Eldik J, Vassilopoulos N, Vegni G, Ventura L, Venus W, Verbeure F, Verlato M, Vertogradov LS, Vilanova D, Vincent P, Vitale L, Vlasov E, Vodopyanov AS, Vrba V, Wahlen H, Walck C, Weierstall M, Weilhammer P, Weiser C, Wetherell AM, Wicke D, Wickens JH, Wielers M, Wilkinson GR, Williams WSC, Winter M, Witek M, Woschnagg K, Yip K, Zach F, Zaitsev A, Zalewska A, Zalewski P, Zavrtanik D, Zevgolatakos E, Zimin NI, Zito M, Zontar D, Zuberi R, Zucchelli GC, Zumerle G. Mean lifetime of theB s 0 meson. ACTA ACUST UNITED AC 1996. [DOI: 10.1007/bf02906957] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
98
|
Mueller H, Kueng W, Schoumacher F, Herzer S, Eppenberger U. Selective regulation of steroid receptor expression in MCF-7 breast cancer cells by a novel member of the heregulin family. Biochem Biophys Res Commun 1995; 217:1271-8. [PMID: 8554586 DOI: 10.1006/bbrc.1995.2905] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
A 52 kDa heregulin secreted by estrogen receptor (ER)-negative human breast cancer cells induced rapid growth of ER-positive MCF-7 breast cancer cells with a stimulatory effect observed at 10(-11)M. This heregulin down-regulated the message for ER in MCF-7 cells within 24 hours after stimulation. Similarly the ER protein was down-regulated within 24 to 48 hours after stimulation of cells. However, this down-regulation occurred without activation of the ER, since the progesterone receptor (PR) level of cells stimulated with the 52 kDa heregulin did not increase over the time period measured. As a control, estradiol down-regulated and activated ER as shown by a pronounced increase in PR content of MCF-7 cells. This finding indicates an important role of this heregulin in the down-regulation of ER in estrogen-dependent human breast cancer cells.
Collapse
|
99
|
Abreu P, Adam W, Adye T, Agasi E, Ajinenko I, Aleksan R, Alekseev GD, Allport PP, Almehed S, Almeida FML, Alvsvaag SJ, Amaldi U, Andreazza A, Antilogus P, Apel WD, Apsimon RJ, Arnoud Y, Asman B, Augustin JE, Augustinus A, Baillon P, Bambade P, Barao F, Barate R, Bardin DY, Barker GJ, Baroncelli A, Barring O, Barrio JA, Bartl W, Bates MJ, Battaglia M, Baubillier M, Baudot J, Becks KH, Begalli M, Beilliere P, Beltran P, Benvenuti AC, Berggren M, Bertrand D, Bianchi F, Bigi M, Bilenky MS, Billoir P, Bjarne J, Bloch D, Blocki J, Blyth S, Bocci V, Bogolubov PN, Bolognese T, Bonesini M, Bonivento W, Booth PSL, Borisov G, Bosio C, Bostjancic B, Bosworth S, Botner O, Boudinov E, Bouquet B, Bourdarios C, Bowcock TJV, Bozzo M, Braibant S, Branchini P, Brand KD, Brenner RA, Briand H, Bricman C, Brillault L, Brown RCA, Brunet JM, Bugge L, Buran T, Buys A, Buytaert JAMA, Caccia M, Calvi M, Camacho Rozas AJ, Campion R, Camporesi T, Capale V, Cankocak K, Cao F, Carena F, Carrilho P, Carroll L, Cases R, Caso C, Castillo Gimenez MV, Cattai A, Cavallo FR, Cerrito L, Chabaud V, Chan A, Chapkin M, Charpentier P, Chaussard L, Chauveau J, Checchia P, Chelkov GA, Chliapnikov P, Chorowicz V, Chrin JTM, Cindro V, Collins P, Contreras JL, Contri R, Cortina E, Cosme G, Cosmo G, Cossutti C, Couchot F, Crawley HB, Crennell D, Crosetti G, Cuevas Maestro J, Czellar S, Dahl-Jensen E, Dahm J, Dalmagne B, Dam M, Damgaard G, Daubie E, Daum A, Dauncey PD, Davenport M, Davies J, Silva W, Defoix C, Delpierre P, Demaria N, Angelis A, Boeck H, Boer W, Brabandere S, Clercq C, Fez Laso MDM, Vaissiere C, Lotto B, Min A, Paula L, Saint-Jean C, Diikstra H, Ciaccio L, Diama F, Dolbeau J, Donszelmann M, Doroba K, Dracos M, Drees J, Dris M, Dufour Y, Dupont F, Edsall D, Ehret R, Ekelof T, Ekspong G, Elsing M, Engel JP, Ershaidat N, Espirito Santo M, Fassouliotis D, Feindt M, Fenyuk A, Ferrer A, Filippas TA, Firestone A, Foeth H, Fokitis E, Fontanelli F, Formenti F, Fousset JL, Franek B, Frenkiel P, Fries DC, Frodesen AG, Fruhwirth R, Fulda-Quenzer F, Furstenau H, Fuster J, Gamba D, Gandelman M, Garcia C, Garcia J, Gaspar C, Gasparini U, Gavillet P, Gazis EN, Gele D, Gerber JP, Giacomelli P, Gillespie D, Gokieli R, Golob B, Golovatyuk VM, Gomez Y Cadenas JJ, Gopal G, Gorn L, Gorski M, Gracco V, Grard F, Graziani E, Grosdidier G, Gunnarsson P, Guy J, Haedinger U, Hahn F, Hahn M, Hahn S, Haider S, Hajduk Z, Hakansson A, Hallgren A, Hamacher K, Hao W, Harris FJ, Hedberg V, Henriques R, Hernandez JJ, Hernando JA, Herquet P, Herr H, Hessing TL, Higon E, Hilke HJ, Hill TS, Holmgren SO, Holt PJ, Holthuizen D, Honore PF, Houlden M, Hrubec J, Huet K, Hultqvist K, Ioannou P, Iversen PS, Jackson JN, Jacobsson R, Jalocha P, Jarlskog G, Jarry P, Jean-Marie B, Johansson EK, Jonker M, Jonsson L, Juillot P, Kaiser M, Kalmus G, Kapusta F, Karlsson M, Karvelas E, Katsanevas S, Katsoufis EC, Keranen R, Khomenko BA, Khovanski NN, King B, Kjaer NJ, Klein H, Klovning A, Kluit P, Koch-Mehrin A, Koehne JH, Koene B, Kokkinias P, Koratzinos M, Korcyl K, Korytov AV, Kostioukhine V, Kourkoumelis C, Kouznetsov O, Kramer PH, Krammer M, Kreuter C, Krolikowski J, Kronkvist I, Krupinski W, Kulka K, Kurvinen K, Lacasta C, Laktineh I, Lambropoulos C, Lamsa JW, Lanceri L, Langefeld P, Lapin V, Last I, Laugier JP, Lauhakangas R, Leder G, Ledroit F, Leitner R, Lemoigne Y, Lemonne J, Lenzen G, Lepeltier V, Lesiak T, Levy JM, Lieb E, Liko D, Lindner R, Lipniacka A, Lippi I, Loerstad B, Lokajicek M, Loken JG, Lopez-Fernandez A, Lopez Aguera MA, Los M, Loukas D, Lozano JJ, Lutz P, Lyons L, Maehlum G, Maillard J, Maio A, Maltezos A, Mandl F, Marco J, Marechal B, Margoni M, Marin JC, Mariotti C, Markou A, Maron T, Marti S, Martinez-Rivero C, Martinez-Vidal F, Matorras F, Matteuzzi C, Matthiae G, Mazzucato M, Cubbin MM, Kay RM, Nulty RM, Medbo J, Meroni C, Meyer WT, Michelotto M, Migliore E, Mikulec I, Mirabito L, Mitaroff WA, Mitselmakher GV, Mjoernmark U, Moa T, Moeller R, Moenig K, Monge MR, Morettini P, Mueller H, Murray WJ, Muryn B, Myatt G, Naraghi F, Navarria FL, Negri P, Nemecek S, Neumann R, Nicolaidou R, Nielsen BS, Niss P, Nomerotski A, Normand A, Obraztsov V, Olshevski AG, Orava R, Osterberg K, Ouraou A, Paganini P, Paganoni M, Pain R, Palka H, Papadopoulou TD, Pape L, Parodi F, Passeri A, Pegararo M, Pennanen J, Peralta L, Pernegger H, Pernicka M, Perrotta A, Petridou C, Petrolini A, Phillips HT, Piana G, Pierre F, Pimenta M, Plaszczynski S, Podobrin O, Pol ME, Polok G, Poropat P, Pozdniakov V, Prest M, Privitera P, Pullia A, Radojicic D, Ragazzi S, Rahmani H, Rames J, Ratoff PN, Read AL, Reale M, Rebecchi P, Redaelli NG, Regler M, Reid D, Renton PB, Resvanis LK, Richard F, Richardson J, Ridky J, Rinaudo G, Ripp I, Romero A, Roncagliolo I, Ronchese P, Roos L, Rosenberg EI, Rosso E, Roudeau P, Rovelli T, Ruckstuhl W, Ruhlmann-Kleider V, Ruiz A, Rybicki K, Saarikko H, Sacquin Y, Sajot G, Salt J, Sanchez J, Sannino M, Schael S, Schneider H, Schyns MAE, Sciolla G, Scuri F, Segar AM, Seitz A, Sekulin R, Seufert R, Shellard RC, Siccama I, Siegrist P, Simonetti S, Simonetto F, Sisakian AN, Skaali TB, Smadja G, Smirnov N, Smirnova O, Smith GR, Sosnowski R, Souza-Santos D, Spassov T, Spiriti E, Squarcia S, Staeck H, Stanescu C, Stapnes S, Stavitski I, Stavropoulos G, Stepaniak K, Stichelbaut F, Stocchi A, Strauss J, Straver J, Strub R, Stugu B, Szczekowski M, Szeptycka M, Tabarelli T, Tchikilev O, Theodosiou GE, Thome Z, Tilquin A, Timmermans J, Timofeev VG, Tkatchev LG, Todorov T, Toet DZ, Tomaradze A, Tome B, Torassa E, Tortora L, Transtromer G, Treille D, Trischuk W, Tristram G, Troncon C, Tsirou A, Tsyganov EN, Turala M, Turluer ML, Tuuva T, Tyapkin IA, Tyndel M, Tzamarias S, Ueberschaer B, Ueberschaer S, Ullaland O, Uvarov V, Valenti G, Vallazza E, Valls Ferrer JA, Velde C, Apeldoorn GW, Dam P, Heijden M, Doninck WK, Eldik J, Vaz P, Vegni G, Ventura L, Venus W, Verbeure F, Verlato M, Vertogradov LS, Vilanova D, Vincent P, Vitale L, Vlasov E, Vodopyanov AS, Vollmer M, Voutilainen M, Wahlen H, Walck C, Wehr A, Weierstall M, Weilhammer P, Wetherell AM, Wickens JH, Wielers M, Wilkinson GR, Williams WSC, Winter M, Witek M, Wormser G, Woschnagg K, Yip K, Yushchenko O, Zach F, Zaitsev A, Zalewska A, Zalewski P, Zavrtanik D, Zevgolatakos E, Zimin NI, Zito M, Zontar D, Zuberi R, Zumerle G. A study of radiative muon-pair events at Z0 energies and limits on an additional Z′ gauge beson. ACTA ACUST UNITED AC 1995. [DOI: 10.1007/bf01578669] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
100
|
Abreu P, Adam W, Adye T, Agasi E, Ajinenko I, Aleksan R, Alekseev GD, Allport PP, Almehed S, Almeida FML, Alvsvaag SJ, Amaldi U, Andreazza A, Antilogus P, Apel WD, Apsimon RJ, Arnoud Y, Asman B, Augustin JE, Augustinus A, Baillon P, Bambade P, Barao F, Barate R, Barbiellini G, Bardin DY, Barker GJ, Baroncelli A, Barring O, Barrio JA, Bartl W, Bates MJ, Battaglia M, Baubillier M, Baudot J, Becks KH, Begalli M, Beilliere P, Belokopytov Y, Beltran P, Benvenuti AC, Berggren M, Bertrand D, Bianchi F, Bigi M, Bilenky MS, Billoir P, Bjarne J, Bloch D, Blocki J, Blyth S, Bocci V, Bogolubov PN, Bolognese T, Bonesini M, Bonivento W, Booth PSL, Borisov G, Bosio C, Bostjancic B, Bosworth S, Botner O, Bouquet B, Bourdarios C, Bowcock TJV, Bozzo M, Braibant S, Branchini P, Brand KD, Brenner RA, Briand H, Bricman C, Brillault L, Brown RCA, Bruckman P, Brunet JM, Bugge L, Buran T, Buys A, Buytaert JAMA, Caccia M, Calvi M, Camacho Rozas AJ, Campion R, Camporesi T, Canale V, Cankocak K, Cao F, Carena F, Carrilho P, Carroll L, Cases R, Caso C, Castillo Gimenez MV, Cattai A, Cavallo FR, Cerrito L, Chabaud V, Chan A, Charpentier P, Chaussard L, Chauveau J, Checchia P, Chelkov GA, Chliapnikov P, Chorowicz V, Chrin JTM, Cindro V, Collins P, Contreras JL, Contri R, Cortina E, Cosme G, Couchot F, Crawley HB, Crennell D, Crosetti G, Maestro JC, Czellar S, Dahl-Jensen E, Dahm J, Dalmagne B, Dam M, Damgaard G, Daubie E, Daum A, Dauncey PD, Davenport M, Davies J, Silva W, Defoix C, Delpierre P, Demaria N, Angelis A, Boeck H, Boer W, Brabandere S, Clercq C, Fez Laso MDM, Vaissiere C, Lotto B, Min A, Paula L, Saint-Jean C, Dijkstra H, Ciaccio L, Djama F, Dolbeau J, Donszelmann M, Doroba K, Dracos M, Drees J, Dris M, Dufour Y, Dupont F, Edsall D, Ehret R, Ekelof T, Ekspong G, Elsing M, Engel JP, Ershaidat N, Santo ME, Fassouliotis D, Feindt M, Fenyuk A, Ferrer A, Fillippas TA, Firestone A, Foeth H, Fokitis E, Fontanelli F, Formenti F, Fousset JL, Franek B, Frenkiel P, Fries DC, Frodesen AG, Fruhwirth R, Fulda-Quenzer F, Furstenau H, Fuster J, Gamba D, Gandelman M, Garcia C, Garcia J, Gaspar C, Gasparini U, Gavillet P, Gazis EN, Gele D, Gerber JP, Giacomelli P, Gillespie D, Gokieli R, Golob B, Golovatyuk VM, Gomez Y Cadenas JJ, Gopal G, Gorn L, Gorski M, Gracco V, Grard F, Graziani E, Grosdidier G, Gunnarsson P, Guy J, Haedinger U, Hahn F, Hahn M, Hahn S, Haider S, Hajduk Z, Hakansson A, Hallgren A, Hamacher K, Hao W, Harris FJ, Hedberg V, Henriques R, Hernandez JJ, Hernando JA, Herquet P, Herr H, Hessing TL, Higon E, Hilke HJ, Hill TS, Holmgren SO, Holt PJ, Holthuizen D, Honore PF, Houlden M, Hrubec J, Huet K, Hultqvist K, Ioannou P, Iversen PS, Jackson JN, Jacobsson R, Jalocha P, Jarlskog G, Jarry P, Jean-Marie B, Johansson EK, Jonker M, Jonsson L, Juillot P, Kaiser M, Kalmus G, Kapusta F, Karlsson M, Karvelas E, Katsanevas S, Katsoufis EC, Keranen R, Khomenko BA, Khovanski NN, King B, Kjaer NJ, Klein H, Klovning A, Kluit P, Koch-Mehrin A, Koehne JH, Koene B, Kokkinias P, Koratzinos M, Korytov AV, Kostioukhine V, Kourkoumelis C, Kouznetsov O, Kramer PH, Krammer M, Kreuter C, Krolikowski J, Kronkvist I, Krupinski W, Kucewicz W, Kulka K, Kurvinen K, Lacasta C, Laktineh I, Lambropoulos C, Lamsa JW, Lanceri L, Langefeld P, Lapin V, Last I, Laugier JP, Lauhakangas R, Leder G, Ledroit F, Leitner R, Lemoigne Y, Lemonne J, Lenzen G, Lepeltier V, Lesiak T, Levy JM, Lieb E, Liko D, Lindner R, Lipniacka A, Lippi I, Loerstad B, Lokajicek M, Loken JG, Lopez-Fernandez A, Lopez Aguera MA, Los M, Loukas D, Lozano JJ, Lutz P, Lyons L, Maehlum G, Maillard J, Maio A, Maltezos A, Marco J, Marechal B, Margoni M, Marin JC, Mariotti C, Markou A, Maron T, Marti S, Martinez-Rivero C, Martinez-Vidal F, Matorras F, Matteuzzi C, Matthiae G, Mazzucato M, Cubbin MM, Kay RM, Nulty RM, Medbo J, Meroni C, Meyer WT, Michelotto M, Migliore E, Mikulec I, Mirabito L, Mitaroff WA, Mitselmakher GV, Mjoernmark U, Moa T, Moeller R, Moenig K, Monge MR, Morettini P, Mueller H, Murray WJ, Muryn B, Myatt G, Naraghi F, Navarria FL, Negri P, Nemecek S, Neumann W, Neumeister N, Nicolaidou R, Nielsen BS, Nikolaenko V, Niss P, Nomerotski A, Normand A, Obraztsov V, Olshevski AG, Orava R, Osterberg K, Ouraou A, Paganini P, Paganoni M, Pain R, Palka H, Papadopoulou TD, Pape L, Parodi F, Passeri A, Pegoraro M, Pennanen J, Peralta L, Perevozchikov V, Pernegger H, Pernicka M, Perrotta A, Petridou C, Petrolini A, Phillips HT, Piana G, Pierre F, Pimenta M, Plaszczynski S, Podobrin O, Pol ME, Polok G, Poropat P, Pozdniakov V, Prest M, Privitera P, Pullia A, Radojicic D, Ragazzi S, Rahmani H, Rames J, Ratoff PN, Read AL, Reale M, Rebecchi P, Redaelli NG, Regler M, Reid D, Renton PB, Resvanis LK, Richard F, Richardson J, Ridky J, Rinaudo G, Ripp I, Romero A, Roncagliolo I, Ronchese P, Ronjin V, Roos L, Rosenberg EI, Rosso E, Roudeau P, Rovelli T, Ruckstuhl W, Ruhlmann-Kleider V, Ruiz A, Saarikko H, Sacquin Y, Sajot G, Salt J, Sanchez J, Sannino M, Schael S, Schneider H, Schyns MAE, Sciolla G, Scuri F, Segar AM, Seitz A, Sekulin R, Sessa M, Seufert R, Shellard RC, Siccama I, Siegrist P, Simonetti S, Simonetto F, Sisakian AN, Skaali TB, Smadja G, Smirnov N, Smirnova O, Smith GR, Sosnowski R, Douza-Santos D, Spassov T, Spiriti E, Squarcia S, Staeck H, Stanescu C, Stapnes S, Stavitski I, Stavropoulos G, Stepaniak K, Stichelbaut F, Stocchi A, Strauss J, Straver J, Strub R, Stugu B, Szczekowski M, Szeptycka M, Tabarelli T, Tchikilev O, Theodosiou GE, Thome Z, Tilquin A, Timmermans J, Timofeev VG, Tkatchev LG, Todorov T, Toet DZ, Tomaradze A, Tome B, torassa E, Tortora L, Transtromer G, Treille D, Tristram G, Troncon C, Tsirou A, Tsyganov EN, Turluer ML, Tuuva T, Tyapkin IA, Tyndel M, Tzamarias S, Ueberschaer B, Ueberschaer S, Ullaland O, Uvarov V, Valenti G, Vallazza E, Valls Ferrer JA, Velde C, Apeldoorn GW, Dam P, Heijden M, Doninck WK, Eldik J, Vaz P, Vegni G, Ventura L, Venus W, Verbeure F, Verlato M, Vertogradov LS, Vilanova D, Vincent P, Vitale L, Vlasov E, Vodopyanov AS, Vollmer M, Voutilainen M, Vrba V, Wahlen H, Walck C, Waldner F, Wehr A, Weierstall M, Weilhammer P, Wetherell AM, Wickens JH, Wielers M, Wilkinson GR, Williams WSC, Winter M, Witek M, Wormser G, Woschnagg K, Yip K, Yushchenko O, Zach F, Zaitsev A, Zalewska A, Zalewski P, Zavrtanik D, Zevgolatakos E, Zimin NI, Zito M, Zontar D, Zuberi R, Zumerle G. Measurement of the $$\Gamma _{b\bar b} /\Gamma _{had} $$ branching ratio of thez by double hemisphere tagging. ACTA ACUST UNITED AC 1995. [DOI: 10.1007/bf01578666] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|